Zai Lab (ZLAB) and Argenx (ARGX) announced that China’s National Medical Products Administration, or NMPA, approved the biologics license application, or BLA, for efgartigimod alfa injection, 1,000mg/vial indicated as an add on to standard therapy for the treatment of adult patients with generalized myasthenia gravis, or gMG, who are anti-acetylcholine receptor, or AChR, antibody positive.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLAB:
Questions or Comments about the article? Write to editor@tipranks.com